Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK
Osteoporosis International · 2024
DOI: 10.1007/s00198-024-07251-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Osteoporosis International, 2024. Verfasst von Fredrik Borgström und 7 weiteren Autor:innen. Beteiligte Einrichtung: Quantify Research, Stockholm, Sweden. fredrik.borgstrom@quantifyresearch.com. Hauptthemen laut MEDLINE: Teriparatide, Cost-Benefit Analysis, Bone Density Conservation Agents, Osteoporotic Fractures. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: UCB, Amgen, Osteoporosis Research Ltd.
Abstract (Originalsprache)
Sequential romosozumab-to-alendronate or sequential teriparatide-to-alendronate can be a cost-effective treatment option for postmenopausal women at very high risk of fracture. PURPOSE: To estimate the 10-year probability of a major osteoporotic fracture (MOF) at which sequential treatment with romosozumab or teriparatide followed by alendronate, compared with alendronate alone, becomes cost-effective in a UK setting. METHODS: A microsimulation model with a Markov structure was used to simulate fractures, costs, and quality-adjusted life years (QALYs), in women receiving sequential treatment with either romosozumab or teriparatide followed by alendronate, compared with alendronate alone. Patients aged 50 to 90 years with a recent MOF, hip or spine fracture were followed from the start of a 5-year treatment until the age of 100 years or death. The analysis had a healthcare perspective. Efficacy of romosozumab, teriparatide and alendronate was derived from phase III randomised controlled trials. Resource use and unit costs were derived from the literature. Cost-effectiveness intervention threshold (CEIT), defined as the 10-year probability of a major osteoporotic fracture at which treatment becomes cost-effective, was compared with clinically appropriate intervention thresholds for bone-forming treatment in women with very high fracture risk as recommended by the UK National Osteoporosis Guideline Group (NOGG). RESULTS: The base case analysis showed that sequential romosozumab-to-alendronate treatment was cost-effective from a 10-year MOF probability of 18-35% and above depending on age and site of sentinel fracture at a willingness to pay (WTP) of £30,000. For teriparatide-to-alendronate, treatment was cost-effective at a 10-year MOF probability of 27-57%. The results were sensitive to pricing of the drugs but relatively insensitive to treatment duration, romosozumab persistence assumptions, and site of sentinel fracture. The CEITs for romosozumab-to-alendronate treatment were lower than the clinical thresholds from the age of 70 years meaning that treatment could be considered both cost-effective and aligned with the NOGG treatment guidelines. By contrast, for teriparatide-to-alendronate the CEITs were higher than the clinical thresholds irrespective of age. However, cost-effective scenarios were found in the presence of strong clinical risk factors in addition to a recent sentinel fracture. CONCLUSION: The results of this study indicate that sequential romosozumab-to-alendronate or teriparatide-to-alendronate treatment can be a cost-effective treatment option for postmenopausal women at very high risk of fracture.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Quantify Research, Stockholm, Sweden. fredrik.borgstrom@quantifyresearch.com.
- Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
- Sahlgrenska Osteoporosis Centre, Institute of Medicine and Clinical Nutrition, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
- MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK.
- NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.
- Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
Förderung
- UCB
- Amgen
- Osteoporosis Research Ltd
Zitieren
APA
Borgström, F., Lorentzon, M., Johansson, H., Harvey, N. C., McCloskey, E., Willems, D., Knutsson, D., & Kanis, J. A. (2024). Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK. Osteoporosis International. https://doi.org/10.1007/s00198-024-07251-w
Vancouver
Borgström F, Lorentzon M, Johansson H, Harvey NC, McCloskey E, Willems D, et al. Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK. Osteoporosis International. 2024. doi:10.1007/s00198-024-07251-w
BibTeX
@article{Borgstrm2024,
author = {Borgström, Fredrik and Lorentzon, Mattias and Johansson, Helena and Harvey, Nicholas C and McCloskey, Eugene and Willems, Damon and Knutsson, Douglas and Kanis, John A},
title = {Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK},
journal = {Osteoporosis International},
year = {2024},
doi = {10.1007/s00198-024-07251-w}
}
EUVIMED